ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

BOTOX® for the Treatment of Platysma Prominence

Phase 2

Completed

Conditions: Platysma Prominence

Interventions: Drug: BOTOX® purified neurotoxin complex
Drug: Placebo

First Posted Date: 2019-04-16

Last Posted Date: 2023-05-03

Lead Sponsor: Allergan

Target Recruit Count: 171

Registration Number: NCT03915067

Locations: 🇺🇸
Dallas Plastic Surgery Institute /ID# 236528, Dallas, Texas, United States
🇨🇦
Sweat Clinics of Canada /ID# 236590, Toronto, Ontario, Canada
🇨🇦
Pacific Derm /ID# 238236, Vancouver, British Columbia, Canada

and more 9 locations

Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China

Phase 4

Completed

Conditions: Macular Edema
Retinal Vein Occlusion

Interventions: Drug: OZURDEX

First Posted Date: 2019-04-09

Last Posted Date: 2023-03-31

Lead Sponsor: Allergan

Target Recruit Count: 150

Registration Number: NCT03908307

Locations: 🇨🇳
The Eye and ENT Hospital Affiliated of Fudan Univesity /ID# 233666, Shanghai, China
🇨🇳
Peking Union Medical College Hospital /ID# 233616, Beijing, Beijing, China
🇨🇳
The First Xiangya Hospital of Central South University /ID# 233627, Changsha Hunan, China

and more 6 locations

International CoolSculpting: Study to Evaluate Patient Satisfaction for Non-Invasive Fat Reduction in Abdomen and/or Flanks (iCOOL)

Not Applicable

Completed

Conditions: Non-invasive Fat Reduction

Interventions: Device: CoolSculpting® System

First Posted Date: 2019-04-09

Last Posted Date: 2023-06-27

Lead Sponsor: Allergan

Target Recruit Count: 120

Registration Number: NCT03909100

Locations: 🇸🇬
Halley Medical Aesthetics, Singapore, Singapore
🇦🇺
Academy Face and Body, Subiaco, Western Australia, Australia
🇸🇬
Dr Benjamin Yim Clinical Aesthetics and Laser Centre, Singapore, Singapore

and more 4 locations

Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Dexamethasone intravitreal implant

First Posted Date: 2019-03-26

Last Posted Date: 2020-06-22

Lead Sponsor: Allergan

Target Recruit Count: 141

Registration Number: NCT03889444

Locations: 🇺🇸
Clinical Trials Registry Team, Irvine, California, United States

Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)

Completed

Conditions: Glaucoma

Interventions: Device: XEN Group
Procedure: Phacoemulsification

First Posted Date: 2019-03-11

Last Posted Date: 2020-11-17

Lead Sponsor: Allergan

Target Recruit Count: 174

Registration Number: NCT03868254

Locations: 🇺🇸
Clinical Trials Registry Team, Irvine, California, United States

BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence

Phase 2

Completed

Conditions: Masseter Muscle Prominence

Interventions: Biological: OnabotulinumtoxinA
Drug: Normal saline

First Posted Date: 2019-03-05

Last Posted Date: 2021-04-28

Lead Sponsor: Allergan

Target Recruit Count: 150

Registration Number: NCT03861936

Locations: 🇺🇸
Cosmetic Laser Dermatology, San Diego, California, United States
🇺🇸
DeNova Research, Chicago, Illinois, United States
🇺🇸
Baumann Cosmetic and Research Institute, Miami, Florida, United States

and more 11 locations

A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia

Phase 3

Completed

Conditions: Presbyopia

Interventions: Drug: Pilocarpine HCl Ophthalmic Solution
Other: Vehicle

First Posted Date: 2019-02-28

Last Posted Date: 2021-12-29

Lead Sponsor: Allergan

Target Recruit Count: 427

Registration Number: NCT03857542

Locations: 🇺🇸
Advanced Vision Care, Los Angeles, California, United States
🇺🇸
South Florida Vision Center, Fort Lauderdale, Florida, United States
🇺🇸
Eye Center South, Dothan, Alabama, United States

and more 32 locations

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

Phase 3

Completed

Conditions: Chronic Migraine

Interventions: Drug: Atogepant 30 mg
Drug: Atogepant 60 mg
Drug: Placebo

First Posted Date: 2019-02-26

Last Posted Date: 2023-02-14

Lead Sponsor: Allergan

Target Recruit Count: 778

Registration Number: NCT03855137

Locations: 🇫🇷
AP-HM - Hopital de la Timone /ID# 236285, Marseille CEDEX 05, Bouches-du-Rhone, France
🇺🇸
DiscoveResearch, Inc /ID# 236274, Bryan, Texas, United States
🇺🇸
Abington Neurological Associates - Abington /ID# 236258, Abington, Pennsylvania, United States

and more 147 locations

Satisfaction With XEN Gel Stent Versus Trabeculectomy for the Treatment of Glaucoma

Completed

Conditions: Glaucoma

First Posted Date: 2019-02-25

Last Posted Date: 2021-10-20

Lead Sponsor: Allergan

Target Recruit Count: 28

Registration Number: NCT03852810

Locations: 🇨🇦
Toronto Ophthalmic Research Innovation Centre, Inc, Toronto, Ontario, Canada
🇩🇪
University of Tübingen, Tübingen, Germany
🇬🇧
Royal Surrey County Hospital, Guildford, United Kingdom

and more 7 locations

Evaluation of Age-Related Skin Changes

Completed

Conditions: Age-related Skin Changes

First Posted Date: 2019-02-15

Last Posted Date: 2019-07-17

Lead Sponsor: Allergan

Target Recruit Count: 100

Registration Number: NCT03842566

Locations: 🇫🇷
Dermscan-Pharmascan, Villeurbanne, France

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy